Trends in enforcement of National Comprehensive Cancer Network financial conflict of interest policy
JNCI Cancer Spectrum · 2024
DOI: 10.1093/jncics/pkae120 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Niloufar Saririan und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Florida, Gainesville, FL 32611, United States. Hauptthemen laut MEDLINE: Conflict of Interest, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
The National Comprehensive Cancer Network (NCCN) financial conflict of interest (FCOI) policy sets dollar maximums for panelists, but violations may occur.
Methods
We studied NCCN Guidelines panelists for the 20 most prevalent cancers, 2013-2022. We included panelists with at least 1 full calendar year of service (“current panelists”) and those who began service during the study period (“new panelists”); NCCN FCOI policy limits ($20 000 from any single company or $50 000 across all companies) apply to both groups. Industry payments were obtained from Open Payments and mapped manually via National Provider Identifier. We calculated industry payments received, excluding the same payment categories as does NCCN (research, meals, travel and lodging). We estimated whether panelists received payments exceeding NCCN limits (“violation”). As a proxy for whether panelists were subsequently disqualified as stipulated, we measured continued service for at least 1 full calendar year (“retention”) subsequent to an estimated violation. We analyzed retention before and after 2016, due to increased scrutiny on NCCN FCOI in 2016.
Results
The annual proportion of current panelists with estimated violations ranged between 0.5% (2020) and 5.8% (2016). Among panelists who did vs did not have violations, retention was 83.6% vs 88.5% during 2014-2015 (odds ratio [OR] = 0.55, 95% CI = 0.26 to 1.31) and 46.6% vs 89.4% during 2017-2020 (OR = 0.10, 95% CI = 0.06 to 0.17). Among new panelists, 2.7% (5/185) had prior-year violations during 2014-2015, as did 5.5% (18/330) during 2017-2021.
Conclusions
Each year, a small portion of panelists receive industry payments exceeding NCCN limits. Since 2016, the likelihood that such panelists will continue to serve has decreased substantially.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- University of Florida, Gainesville, FL 32611, United States.
- Downstate School of Medicine, State University of New York, New York, NY 11203, United States.
- Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10017, United States.
- Department of Health Care Programs, NORC at the University of Chicago, Chicago, IL 60603, United States.
- Delfi Diagnostics, Baltimore, MD 21224, United States.
ORCID-Profile: Niloufar Saririan, Dedipya Bhamidipati, Pranam Dey, Sonia Persaud, Nirjhar Chakraborty, Sara Tabatabai, Grace Gallagher, Niti U Trivedi, Aaron P Mitchell
Förderung
- NCI NIH HHS
Zitieren
APA
Saririan, N., Bhamidipati, D., Dey, P., Persaud, S., Chakraborty, N., Tabatabai, S., Gallagher, G., Trivedi, N. U., & Mitchell, A. P. (2024). Trends in enforcement of National Comprehensive Cancer Network financial conflict of interest policy. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae120
Vancouver
Saririan N, Bhamidipati D, Dey P, Persaud S, Chakraborty N, Tabatabai S, et al. Trends in enforcement of National Comprehensive Cancer Network financial conflict of interest policy. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae120
BibTeX
@article{Saririan2024,
author = {Saririan, Niloufar and Bhamidipati, Dedipya and Dey, Pranam and Persaud, Sonia and Chakraborty, Nirjhar and Tabatabai, Sara and Gallagher, Grace and Trivedi, Niti U and Mitchell, Aaron P},
title = {Trends in enforcement of National Comprehensive Cancer Network financial conflict of interest policy},
journal = {JNCI Cancer Spectrum},
year = {2024},
doi = {10.1093/jncics/pkae120}
}
EUVIMED